Author

Thomas Botton

InsermORCID 0000-0001-9079-7014Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Thomas Botton1 paper

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:human· 1 Research Focus:metabolism & bioenergetics· 1

Frequent Co-Authors

Ana Carolina Bastos Sant'Anna SilvaiD· 1 shared Caroline RobertiD· 1 shared Cyril RoncoiD· 1 shared Fanny Bonnard· 1 shared Frédéric Larbret· 1 shared Henri MontaudiéiD· 1 shared Issam Ben‐SahraiD· 1 shared Michaël CerezoiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Ana Carolina Bastos Sant'Anna SilvaORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

MELK controls tumor metabolism to promote resistance to melanoma therapy

Ana Carolina Bastos Sant'Anna Silva, Patricia Abbe, Sophie Pagnotta, Nívea Dias Amoêdo, Michael D. Torno, Fanny Bonnard, Thomas Botton, Frédéric Larbret, Cyril Ronco, Henri Montaudié, Issam Ben‐Sahra, Caroline Robert, Thierry Passeron, Rodrigue Rossignol, Michaël Cerezo, Stéphane Rocchi

This study identifies MELK as a key driver of metabolic adaptation and therapy resistance in melanoma, showing that inhibiting MELK can sensitize resistant cells to immunotherapy.

bioRxiv · Dec 31, 2025 · PreprintCancer Biology